Results 161 to 170 of about 2,532,063 (299)

Bbeta-adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy: regulation by beta- but not alpha1-adrenergic stimulation.

open access: yes, 1999
Pressure overload ventricular hypertrophy is accompanied by dysfunctional beta-adrenergic receptor signaling due to increased levels of the beta-adrenergic receptor kinase-1, which phosphorylates and desensitizes beta-adrenergic receptors. In this study,
Koch, Walter J   +3 more
core   +1 more source

Cardiovascular Plasticity and Adaptation of High‐Altitude Birds and Mammals

open access: yesIntegrative Zoology, EarlyView.
This schematic depicts the cardiovascular adaptations of mammals and birds to high‐altitude hypoxia. It highlights key phenotypic changes in oxygen transport and cardiac responses, driven by molecular mechanisms including transcriptional regulation and genetic modifications.
Huishang She, Yanhua Qu
wiley   +1 more source

6‐Nitrodopamine as a Novel Mediator of Prostatic Smooth Muscle Function in Mouse and Human

open access: yesAndrology, EarlyView.
ABSTRACT Background Epithelium‐derived catecholamines contribute to local regulation of genitourinary smooth muscle function, but the role of the endogenous 6‐nitrodopamine (6‐ND) in the prostate remains unknown. Objectives To determine whether 6‐ND is produced by mouse and human prostate and its role in smooth muscle regulation.
Alline Araujo Curiel   +12 more
wiley   +1 more source

Trends in glaucoma diagnosis and medical management in Germany: A nationwide claims data analysis over 10 years

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose Analysing longitudinal trends in recorded diagnosis and medical management of glaucoma in Germany over a 10‐year period. Methods A retrospective cohort study using nationwide outpatient claims and prescription data from the German statutory health insurance system.
Somar M. Hasan   +8 more
wiley   +1 more source

PDE4D and PDE3B orchestrate distinct cAMP microdomains in 3T3‐L1 adipocytes

open access: yesBritish Journal of Pharmacology, EarlyView.
Basal conditions: •Ins/PDE3B lowers cytoplasmic cAMP (cyt‐cAMP) without affecting plasma membrane cAMP (pm‐cAMP). •Insulin decreases lipid droplet cAMP (LD‐cAMP) independent of PDE3B. •FGF1/PDE4D modestly reduces both cyt‐ and pm‐cAMP, while PDE4D alone can modulate LD‐cAMP. ISO stimulation: •Ins/PDE3B has minimal impact on cyt‐cAMP.
Johannes Krier   +9 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade   +7 more
wiley   +1 more source

Cancer pain: current practice and emerging targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye   +5 more
wiley   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy